BU commentary: Vitamin D supplementation was

For more than 100 years, it has been believed that sunlight and vitamin D deficiency were associated with the risk for many deadly cancers including colorectal, prostate and breast. But some scientists remained skeptical that this nutrient provides any benefit for reducing cancer risk and morbidity and mortality and several randomized controlled trials that have supported this doubt.

However, in a new commentary in JAMA Network Open, Michael F. Holick, PhD, MD, professor of medicine, pharmacology, physiology & biophysics and molecular medicine at Boston University Chobanian & Avedisian School of Medicine, explores the controversy as to whether improving vitamin D status has any benefit for reducing risk of developing cancer as well as improving relapse-free and mortality outcomes.

Related Keywords

Boston , Massachusetts , United States , Eric Anthony Nepute , Carbogen Amcis , Smichaelf Holick , Hypera Pharma , Boston University Chobanian Avedisian School Of Medicine , Method Of Research , Pulse Pharmaceuticals , Boston University Chobanian , Avedisian School , Vitamind Supplements , Relapseor Death , Digestive Tract Cancer , Post Hoc Analysis , Digestive Tract , Faes Farma , Menarini India , Novel Use ,